Author pages are created from data sourced from our academic publisher partnerships and public sources.
Combination of 5‐azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia
The treatment of myelodysplastic syndromes (MDS) remains a challenge to the clinician despite recent advances. Many patients will either not respond or will have only limited and/or brief responses… Expand
Clinical response of myelodysplastic syndromes patients to treatment with coenzyme Q10.
The myelodysplastic syndromes (MDS) are a collection of hematopoietic disorders with varying degrees of mono- to trilineage cytopenias and bone marrow dysplasia. In recent years much progress has… Expand
Translational research in myelodysplastic syndromes.
- A. Raza, H. Qawi, Murtaza Mehdi, M. Mumtaz, Naomi Galili
- Reviews in clinical and experimental hematology
- 1 December 2004
The myelodysplastic syndromes (MDS) are receiving unusual attention recently as great strides have been made in understanding the biology. Recognition that excessive cytokine-induced apoptosis plays… Expand
Effect of mutations in distinct components of the PI3K/AKT/mTOR pathway on sensitivity to endocrine therapy in estrogen receptor (ER)-positive breast cancer.
532 Background: Aberrations of the PI3K/AKT/mTOR pathway are common in ER-positive breast cancer and may be associated with endocrine-resistance. We hypothesized that, since the majority of… Expand
Abstract 4670: A novel companion diagnostic predicts response to the PARP inhibitor rucaparib in ovarian cancer
Background: Genomic studies suggest that ∼50% of high-grade serous ovarian cancers (OC) have homologous recombination deficiency (HRD). Germline BRCA1/2 mutations (gBRCAmut) are expected to account… Expand
Low incidence of JAK2 and FLT3 mutations in patients with chronic myelomonocytic leukemia (CMML)
1293 The recent finding of a somatic point mutation in the JAK2 tyrosine kinase (V617F) pseudokinase domain of the majority of patients with myloproliferative disorders has greatly increased the… Expand
Abstract P3-05-06: Evolution of genomic alterations on endocrine therapy and mTOR inhibition in estrogen receptor (ER)-positive breast cancer
Background: Endocrine therapy (ET) and mTOR inhibition are important treatment strategies in ER-positive breast cancer, but no specific genomic alterations reliably predict benefit. Because tumors… Expand
Evaluation of possible linkage between everolimus benefit in estrogen receptor (ER)-positive breast cancer and genomic alterations of the PI3K/AKT/mTOR pathway.
530 Background: Everolimus, which inhibits mTOR, is used to treat metastatic ER-positive breast cancer after aromatase inhibitor failure. Because not all patients benefit and toxicity can be prohib...
Tumor biopsies in high grade ovarian cancer: Clinical utility and challenges for biomarker-directed therapy.
5539 Background: Molecular profiling of tissue obtained with a biopsy aids detection of predictive and pharmacodynamic biomarkers to guide patient (pt) selection and treatment. This study assesses ...
Encouraging hematopoietic and cytogenetic responses to coenzyme Q10 (coQ10) in patients with low and intermediate-1 risk (Int-1) myelodysplastic syndromes (MDS
Proc Amer Assoc Cancer Res, Volume 46, 2005 2544 Excessive intramedullary apoptosis can explain the variable cytopenias, which are the hallmark of the disease, in a majority of MDS patients. Since… Expand